Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Communicable

Communicable artwork

Communicable E14 - Substandard and falsified antimicrobials: what is their effect on patients and on AMR?

Nov 18, 202452 minAudio
ShareXLinkedInFacebookWhatsAppEmail

Substandard and falsified (SF) antimicrobials are a neglected global health problem and have been implicated as drivers of antimicrobial resistance (AMR). Substandard medicines are authorized medical products that fail to meet either their quality standards or their specifications, whereas falsified medicines are those that deliberately and fraudulently misrepresent their identity, composition or source. Host Angela Huttner is joined by Pernette Bourdillon Esteve, Technical Officer for the World Health Organization’s Substandard/falsified Medical Products group, and Ben Cooper, epidemiologist at Oxford University and head of its Drug-Resistant Infection and Disease Dynamics (DRIaDD), to explore the effects of SF antimicrobials on people and AMR. This episode was edited by Kathryn Hostettler and peer-reviewed by Dr. Arjana Zerja of Mother Teresa University Hospital in Tirana, Albania. Literature Cavany S et al. Nat Commun 14, 6153 (2023). doi: 10.1038/s41467-023-41542-w WHO Global Surveillance and Monitoring System for substandard and falsified medical products (2017). https://www.who.int/publications/i/item/9789241513425

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Communicable E67: New antifungals & how to use them

    Nov 15, 202650 minAudio

    In this episode of Communicable, hosts Annie Joseph and Josh Nosanchuk welcome Neil Stone and Jeniel Nett to discuss new and emerging antifungal treatments, including ibrexafungerp, rezafungin and olorofim, among...

    Credit the people on this episode

  2. Communicable E66: Diagnostics in the AMR era

    Nov 1, 202651 minAudio

    Ahead of World Antimicrobial Resistance Awareness Week (WAAW), Communicable presents a special episode exploring the role of diagnostics within the space of antimicrobial resistance (AMR). Hosts Thomas Tängdén and Annie...

    Credit the people on this episode

  3. Communicable E65: Quarterly catch-up (October 2026 edition)

    Oct 18, 202649 minAudio

    In this episode of Communicable, Emily McDonald returns for another ‘Quarterly catch-up’ and is joined by Angela Huttner as co-host. Together, they review four recent randomised clinical trials, focusing on antibiotic...

    Credit the people on this episode

  4. Communicable E64: Getting micro on macrolides for community-acquired pneumonia

    Oct 4, 202650 minAudio

    In this episode of Communicable, hosts Emily McDonald and Marc Bonten are joined by Sylvain Lother and Valentijn Schweitzer for a discussion on the use of macrolides in community-acquired pneumonia. Together, they...

    Credit the people on this episode

  5. Communicable E63: Does oseltamivir harm critically ill patients? The REMAP-CAP results

    Sep 20, 20261 hr 3 minAudio

    At the Critical Care Reviews meeting in Belfast in June this year, REMAP-CAP investigators presented results suggesting that oseltamivir may be harmful in critically ill patients with influenza, upending a long-standing...

    Credit the people on this episode